Session

Perioperative chemotherapy and advanced disease - increasing experience and new aspects

Poster Session 13

  • Location:
    Room Vienna, North Hall (Level 1)
  • Chairs:
     P. Patel, Birmingham (GB)
     C.N. Sternberg, Rome (IT)
     J.A. Witjes, Nijmegen (NL)
  • Aims and objectives of this session

    This session will highlight new data on systemic perioperative therapy and advanced bladder cancer, including chemotherapy, immunotherapy and prediction of outcome.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 170
Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052

By: Powles T.1, Bellmunt J.2, Castellano D.3, O’Donnell P.4, Grivas P.5, Vuky J.6, Plimack E.7, Hahn N.8, Balar A.9, Pang L.10, Savage M.10, Perini R.10, Keefe S.10, Bajorin D.11, De Wit R.12

Institutes: 1Barts Cancer Institute, Queen Mary University of London, Dept. of Experimental Cancer Medicine, London, United Kingdom, 2Dana-Farber Cancer Institute, Dept. of Genitourinary Oncology, Boston, United States of America, 3Hospital Universitario 12 De Octubre, Dept. of Medicine, Madrid, Spain, 4The University of Chicago Medical Centre, Dept. of Medicine, Chicago, United States of America, 5Cleveland Clinic, Dept. of Hematology and Oncology, Cleveland, United States of America, 6Oregon Health & Science University, Dept. of Oncology, Portland, United States of America, 7Fox Chase Cancer Center, Dept. of Hematology and Oncology, Philadelphia, United States of America, 8Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Dept. of Oncology and Urology, Baltimore, United States of America, 9Perlmutter Cancer Center, NYU Langone Medical Center, Dept. of Medicine, New York, United States of America, 10Merck & Co., Inc., Dept. of Clinical Oncology, Kenilworth, United States of America, 11Memorial Sloan Kettering Cancer Center, Dept. of Medical Oncology, New York, United States of America, 12Erasmus MC Cancer Institute, Dept. of Urology and Oncology, Rotterdam, The Netherlands

171
Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): Comparing outcomes of immunotherapy (IT) vs. single agent and doublet chemotherapy (CT)

By: Necchi A.1, Raggi D.1, Sonpavde G.2, Giannatempo P.3, Mariani L.4, Galsky M.5, Bellmunt J.6, Miceli R.4

Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2UAB Comprehensive Cancer Center, Dept. of Medical Oncology & Hematology, Birmingham, United States of America, 3Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 4Fondazione IRCCS Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, 5Mount Sinai School of Medicine, Tisch Cancer Institute, Dept. of Medical Oncology, New York, United States of America, 6Dana-Farber Cancer Institute and Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America

172
Adjuvant chemotherapy vs. observation following radical cystectomy for pT3-4 and/or pN+ urothelial carcinoma of the bladder previously treated with neoadjuvant chemotherapy

By: Seisen T.1, Jamzadeh A.2, Vetterlein M.1, Von Landenberg N.1, Gild P.1, Menon M.2, Rouprêt M.3, Sun M.1, Choueiri T.4, Bellmunt J.4, Trinh Q.-D.1

Institutes: 1Brigham and Women’s Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, 2Henry Ford Health System, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, 3Pitié-Salpêtrière, APHP, University Paris VI, Department of Urology, Paris, France, 4Dana Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America

173
Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder

By: Seisen T.1, Sonpavde G.2, Kachroo N.3, Lipsitz S.4, Leow J.1, Menon M.3, Gild P.1, Von Landenberg N.1, Rouprêt M.5, Kibel A.1, Sun M.1, Pal S.6, Bellmunt J.7, Choueiri T.7, Trinh Q-D.1

Institutes: 1Brigham and Women’s Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, 2University of Alabama At Birmingham, Division of Hematology-Oncology, Department of Medicine, Birmingham, United States of America, 3Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, 4Brigham and Women’s Hospital, Harvard Medical School and Harvard T.H. Chan School of Public Health, Center for Surgery and Public Health, Boston, United States of America, 5Pitié-Salpêtrière, APHP, University Paris VI, Dept. of Urology, Paris, France, 6City of Hope Comprehensive Cancer Center, Dept. of Medical Oncology & Experimental Therapeutics, Duarte, United States of America, 7Dana Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America

174
Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase 2 study

By: Necchi A.1, Lo Vullo S.2, Raggi D.1, Giannatempo P.1, Nicolai N.3, Piva L.3, Biasoni D.3, Catanzaro M.3, Torelli T.3, Stagni S.3, Calareso G.4, Togliardi E.5, Colecchia M.6, Busico A.6, Perrone F.6, Pennati M.7, Zaffaroni N.7, Mariani L.2, Salvioni R.3

Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Fondazione IRCCS – Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, 3Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 4Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, 5Fondazione IRCCS – Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, 6Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, 7Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Experimental Oncology and Molecular Medicine, Milan, Italy

175
Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial

By: Hanna N.1, Trinh Q.-D.1, Sammon J.2, Seisen T.1, Vetterlein M.1, Moreira R.3, Preston M.1, Lipsitz S.1, Bellmunt J.3, Menon M.2, Choueiri T.3, Abdollah F.2

Institutes: 1Brigham and Women’s Hospital, Harvard Medical School, Dept. of Urology, Boston, United States of America, 2Henry Ford Hospital, Dept. of Urology, Detroit, United States of America, 3Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America

* 176
An inconvenient truth: Difference between patient-reported and doctor-reported outcomes in advanced urothelial carcinoma

By: Hamano I.1, Hatakeyama S.1, Narita T.1, Fukushi K.1, Yamamoto H.1, Soma O.1, Matsumoto T.1, Tobisawa Y.1, Yoneyama T.2, Imai A.1, Yoneyama T.1, Hashimoto Y.2, Koie T.1, Ohyama C.1

Institutes: 1Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Hirosaki University School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan

177
Survival benefit of neoadjuvant chemotherapy for muscle invasive bladder cancer in elderly patients

By: Hamano I.1, Hatakeyama S.1, Oikawa M.1, Narita T.1, Hagiwara K.1, Tanaka T.1, Noro D.1, Yuki T.1, Yamamoto H.1, Yoneyama T.2, Imai A.1, Yoneyama T.1, Hashimoto Y.2, Koie T.1, Ohyama C.1

Institutes: 1Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Hirosaki University School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan

178
The pathological and clinical response of the luminal and basal subtypes of muscle-invasive bladder cancer to neoadjuvant cisplatin-based chemotherapy and radical cystectomy depend on the immunohistochemical classification system

By: Zhang R.1, Chen H.1, Xia J.2, Shi O.3, Cao M.1, Jin D.1, Li C.4, Zhuang G.5, Liu Q.2, Xue W.1, Radvanyi F.6, Allory Y.7, Huang Y.1

Institutes: 1Shanghai Renji Hospital, Dept. of Urology, Shanghai, China, 2Shanghai Renji Hospital, Dept. of Pathology, Shanghai, China, 3Shanghai Jiao Tong University School of Medicine, Dept. of Epidemiology and Statistics, Shanghai, China, 4Chinese Academy of Sciences, Chinese Academy of Sciences Protein Science Core Facility Center, Institute of Biophysics, Beijing, China, 5Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, State Key Laboratory of Oncogenes and Related Genes, Shanghai, China, 6Institut Curie, CNRS, UMR 144, Paris, France, 7AP-HP, Hôpitaux Universitaires Henri-Mondor, Dept. of Pathology, Créteil, France

179
Impact of adjuvant chemotherapy in patients with pT3NanyM0 upper tract urothelial cancer following radical nephroureterectomy

By: Song W.1, Choi Y.H.1, Chung H.W.1, Lee C.U.1, Na J.P.1, Choi S.M.2, Sung H.H.1, Jeon H.G.1, Jeong B.C.1, Seo S.I.1, Jeon S.S.1, Choi H.Y.1, Lee H.M.1

Institutes: 1Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea, 2Gyeongsang National University Hospital, Dept. of Urology, Jinju, South Korea

180
Multimodal bladder preservation technique for muscle invasive bladder cancer: Results from a prospective trial

By: Inamoto T.1, Takahara K.2, Ibuki N.2, Takai T.2, Uchimoto T.3, Saito K.2, Tanda N.2, Yoshikawa Y.2, Minami K.2, Hirano H.2, Nomi H.2, Azuma H.2, Yamamoto K.4, Shinbo T.4, Yamamoto K.4, Narumi Y.4

Institutes: 1Osaka Medical College, Osaka, Japan, 2Osaka Medical College, Dept. of Urology, Osaka, Japan, 3Osaka Medical College Mishima-Minami Hospital, Dept. of Urology, Osaka, Japan, 4Osaka Medical College, Dept. of Radiology, Osaka, Japan

Aspects on perioperative chemotherapy
 C.N. Sternberg, Rome (IT)